Analysts think HURA stock price could increase by 297%
Apr 07, 2025, 11:25 AM
11.98%
What does HURA do
Kintara Therapeutics, a biopharmaceutical company based in San Diego, develops new cancer therapies, including the late-stage REM-001 for cutaneous metastatic breast cancer and VAL-083 for drug-resistant solid tumors. The company went public on July 12, 2016, and has two employees.
5 analysts think HURA stock price will increase by 297.01%. The current median analyst target is $13.26 compared to a current stock price of $3.34. The lowest analysts target is $9.34 and the highest analyst target is $15.75.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
